SavedAdd your journal

Journals / ANKEM Dergisi / 2009 / Cilt: 23 - Sayı: 3

Clinical use of voriconazole, a new wide-spectrum triazole, in veterinary practice

Veteriner pratiğinde geniş antifungal spektrumlu yeni triazol: Vorikonazol

Asiye Nur Meltem KABLAN
MEHMET ERMAN OR
Abdülkadir UYSAL
Pages
149–153
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our review it is aimed to give further information about voriconazoles’ clinical effects and use in veterinary practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Azoles have maintained a key role in the treatment of invasive fungal infections which have a growing importance, especially in immunocompromised patients.
📊
Key Findings & Data:Voriconazole is a second generation new triazole antifungal agent with potent activity against many clinically significant fungal pathogens, including Aspergillus, Candida, Cryptococcus neoformans and some less common moulds.
💡
Conclusion & Impact:In our review it is aimed to give further information about voriconazoles’ clinical effects and use in veterinary practice.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Azoles have maintained a key role in the treatment of invasive fungal infections which have a growing importance, especially in immunocompromised patients. Voriconazole is a second generation new triazole antifungal agent with potent activity against many clinically significant fungal pathogens, including Aspergillus, Candida, Cryptococcus neoformans and some less common moulds. Several recent studies have indicated that voriconazole is also highly effective in therapy of clinical cases. In our review it is aimed to give further information about voriconazoles’ clinical effects and use in veterinary practice.

Özet

Azoller artan öneme sahip invaziv fungal infeksiyonların tedavisinde özellikle immunolojik açıdan sorunlu olan hastalarda anahtar rol üstlenirler. Vorikonazol Aspergillus, Candida, Cryptococcus neoformans ve daha az görülen bazı küfler gibi klinik olarak önemli olan fungal patojenlere karşı geniş spektrumlu güçlü aktivitesiyle ikinci jenerasyon yeni triazol antifungal ajandır. Son zamanlarda yapılan pek çok çalışma vorikonazolün klinik etkinliğinin oldukça büyük olduğunu göstermiştir. Derlememizde vorikonazolün veteriner pratiğinde kullanımı hakkında bilgi verilmektedir.

🔖

Cite This Article

KABLAN, A. N. M., OR, M. E., UYSAL, A. (2009). Clinical use of voriconazole, a new wide-spectrum triazole, in veterinary practice. ANKEM Dergisi, Cilt: 23 - Sayı: 3, 149–153. https://ajindex.com/articles/189467

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Andes D, Marchillo K, Stamstad T, Conklin R: In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model, Antimicrob Agents Chemother 2003;47(10):3165-9
  2. Anonim: Voriconazole: new preparation, invasive aspergillosis: benefits to be confirmed, Prescrire Int 2004;13(69):13-6
  3. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy, Drugs 2004;64(18):1997-2020
  4. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ: Topical and oral voriconazole in the treatment of fungal keratitis, Am J Ophtalmol 2007;143(1):151-3
  5. Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC: Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses, Am J Vet Res 2006;67(2):296-301
  6. Colitz CM, Latimer FG, Cheng H, Chan KK, Reed SM, Pennick GJ: Pharmacokinetics of voricona- zole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses, Am J Vet Res 2007;68(10):1115-21
  7. Davis JL, Salmon JH, Papich MG: Pharmacokinetics of voriconazole after oral and intravenous administration to horses, Am J Vet Res 2006;67(6):1070-5
  8. De Pauw BE: New antifungal agents and prepara tions, Int J Antimicrob Agents 2000;16(2):147-50
  9. Elad S, Bitan M, Olshtain-Pops K et al: Successful treatment of oral invasive aspergillosis with voriconazole; Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99(4):428
  10. Herbrecht R: Voriconazole: therapeutic review of a new azole antifungal, Expert Rev Anti Infect Ther 2004;2(4):485-97
  11. Hoffman HL, Rathbun RC: Review of the safety and efficacy of voriconazole, Expert Opin Investig Drugs 2002;11(3):409-29
  12. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HE: Voriconazole, Clin Ther 2003; 25(5):1321-81
  13. Keady S, Thacker M: Voriconazole in the treatment of invasive fungal infections, Intensive Crit Care Nurs 2005;21(6):370-3
  14. Kirkpatrick WR, Perea P, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis, Antimicrob Agents Chemother 2002;46(8):2564-8
  15. Kofla G, Ruhnke M: Voriconazole: Review of a broad spectrum triazole antifungal agents, Expert Opin Pharmacother 2005;6(7):1215-29
  16. Muijsers RB, Goa KL, Scott LJ: Voriconazole in the treatment of invasive aspergillosis, Drugs 2002;62(18):2655-66
  17. Polak A: